CN107847590B - 针对白细胞介素36受体(il-36r)的抗体 - Google Patents

针对白细胞介素36受体(il-36r)的抗体 Download PDF

Info

Publication number
CN107847590B
CN107847590B CN201680034793.6A CN201680034793A CN107847590B CN 107847590 B CN107847590 B CN 107847590B CN 201680034793 A CN201680034793 A CN 201680034793A CN 107847590 B CN107847590 B CN 107847590B
Authority
CN
China
Prior art keywords
ser
thr
gly
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680034793.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN107847590A (zh
Inventor
P·鲍尔斯
A·J·麦克奈特
D·J·金
M·隆代伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anaptysbio Inc
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Priority to CN202210803364.8A priority Critical patent/CN115925932A/zh
Publication of CN107847590A publication Critical patent/CN107847590A/zh
Application granted granted Critical
Publication of CN107847590B publication Critical patent/CN107847590B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201680034793.6A 2015-04-15 2016-04-15 针对白细胞介素36受体(il-36r)的抗体 Active CN107847590B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210803364.8A CN115925932A (zh) 2015-04-15 2016-04-15 针对白细胞介素36受体(il-36r)的抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562147824P 2015-04-15 2015-04-15
US62/147,824 2015-04-15
PCT/US2016/027676 WO2016168542A1 (en) 2015-04-15 2016-04-15 Antibodies directed against interleukin 36 receptor (il-36r)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210803364.8A Division CN115925932A (zh) 2015-04-15 2016-04-15 针对白细胞介素36受体(il-36r)的抗体

Publications (2)

Publication Number Publication Date
CN107847590A CN107847590A (zh) 2018-03-27
CN107847590B true CN107847590B (zh) 2022-07-26

Family

ID=57126337

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680034793.6A Active CN107847590B (zh) 2015-04-15 2016-04-15 针对白细胞介素36受体(il-36r)的抗体
CN202210803364.8A Pending CN115925932A (zh) 2015-04-15 2016-04-15 针对白细胞介素36受体(il-36r)的抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210803364.8A Pending CN115925932A (zh) 2015-04-15 2016-04-15 针对白细胞介素36受体(il-36r)的抗体

Country Status (14)

Country Link
US (4) US10526410B2 (cg-RX-API-DMAC7.html)
EP (2) EP4176900A1 (cg-RX-API-DMAC7.html)
JP (4) JP6913026B2 (cg-RX-API-DMAC7.html)
KR (1) KR102666920B1 (cg-RX-API-DMAC7.html)
CN (2) CN107847590B (cg-RX-API-DMAC7.html)
AU (1) AU2016248208B2 (cg-RX-API-DMAC7.html)
CA (1) CA2982555A1 (cg-RX-API-DMAC7.html)
DK (1) DK3283110T3 (cg-RX-API-DMAC7.html)
ES (1) ES2914243T3 (cg-RX-API-DMAC7.html)
MX (2) MX2017013080A (cg-RX-API-DMAC7.html)
PL (1) PL3283110T3 (cg-RX-API-DMAC7.html)
RU (1) RU2745898C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201708061TA (cg-RX-API-DMAC7.html)
WO (1) WO2016168542A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2780373T1 (sl) 2011-11-16 2019-12-31 Boehringer Ingelheim International Gmbh Protitelesa proti IL-36R
US10526410B2 (en) * 2015-04-15 2020-01-07 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (IL-36R)
EP3601350A1 (en) * 2017-03-27 2020-02-05 Boehringer Ingelheim International GmbH Anti il-36r antibodies combination therapy
EP3400962A1 (en) 2017-05-09 2018-11-14 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Inhibitors of il-38 for use in treating and/or preventing cancer in a subject
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2019177883A2 (en) * 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
AU2019236105B2 (en) * 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
CA3098040A1 (en) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Non-human animal models of ditra disease and uses thereof
KR102895164B1 (ko) * 2018-07-16 2025-12-04 리제너론 파마슈티칼스 인코포레이티드 항-il36r 항체
CN110818796B (zh) * 2018-08-09 2022-11-08 东莞市朋志生物科技有限公司 一种抗人ca153蛋白的重组抗体
MX2021007589A (es) 2018-12-21 2021-12-10 23Andme Inc Anticuerpos anti il-36 y procedimientos de uso de estos.
KR20210119407A (ko) * 2018-12-27 2021-10-05 베링거 인겔하임 인터내셔날 게엠베하 수장 족저 농포증 치료용 항-il-36r 항체
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
US11730812B2 (en) 2019-03-08 2023-08-22 Boehringer Ingelheim International Gmbh Anti-IL-36R antibody formulations
CN114929738B (zh) * 2019-08-07 2026-01-02 水肺治疗公司 抗nampt抗体及其用途
JP7811772B2 (ja) * 2019-12-05 2026-02-06 学校法人東京薬科大学 筋組織の減少を抑制するための組成物
AR120913A1 (es) * 2019-12-27 2022-03-30 Teijin Pharma Ltd Anticuerpo que inhibe específicamente la señalización de il-36r
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
MX2023000763A (es) * 2020-07-17 2023-02-13 Boehringer Ingelheim Int Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
WO2022026832A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for ichthyosis
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
US20240002517A1 (en) * 2020-12-16 2024-01-04 CSL Innovation Pty Ltd Protein formulations and uses thereof
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
WO2022150642A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
BR112023014103A2 (pt) * 2021-03-04 2023-10-10 Boehringer Ingelheim Int Métodos para o tratamento de gpp
EP4305207A2 (en) 2021-03-12 2024-01-17 Boehringer Ingelheim International GmbH Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
EP4337257A1 (en) * 2021-05-12 2024-03-20 AnaptysBio, Inc. Antibody composition
WO2023285362A1 (en) 2021-07-12 2023-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
TW202323293A (zh) * 2021-10-29 2023-06-16 新加坡商創響私人有限公司 新型抗il-36r抗體
CN115724975B (zh) * 2022-10-20 2026-06-09 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013016220A1 (en) * 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
CN104080808A (zh) * 2011-11-16 2014-10-01 勃林格殷格翰国际有限公司 抗il-36r抗体

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
AU2001233212A1 (en) 2000-02-02 2001-08-14 Schering Corporation Mammalian cytokines; receptors; related reagents and methods
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US8034771B2 (en) 2006-09-08 2011-10-11 Amgen Inc. IL-1F6 polypeptides
JP5675109B2 (ja) 2007-02-20 2015-02-25 アナプティスバイオ インコーポレイティッド ライブラリーの生成方法及びその使用
KR20110048536A (ko) 2008-08-28 2011-05-11 와이어쓰 엘엘씨 자가면역 질병에서 il-22, il-17 및 il-1 패밀리 시토킨의 용도
HUE037186T2 (hu) * 2011-12-28 2018-08-28 Immunoqure Ag Eljárás humán antitestek izolálására
JP6162319B2 (ja) * 2013-03-12 2017-07-12 デシミューン セラピューティクス,インコーポレイテッド ヒト化抗n2抗体
US10526410B2 (en) * 2015-04-15 2020-01-07 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (IL-36R)
EP3601350A1 (en) 2017-03-27 2020-02-05 Boehringer Ingelheim International GmbH Anti il-36r antibodies combination therapy
WO2019177883A2 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
AU2019236105B2 (en) 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
KR102895164B1 (ko) 2018-07-16 2025-12-04 리제너론 파마슈티칼스 인코포레이티드 항-il36r 항체
MX2021007589A (es) 2018-12-21 2021-12-10 23Andme Inc Anticuerpos anti il-36 y procedimientos de uso de estos.
KR20210119407A (ko) 2018-12-27 2021-10-05 베링거 인겔하임 인터내셔날 게엠베하 수장 족저 농포증 치료용 항-il-36r 항체
US11730812B2 (en) 2019-03-08 2023-08-22 Boehringer Ingelheim International Gmbh Anti-IL-36R antibody formulations
EP3974445A4 (en) 2019-05-20 2023-03-22 Nantong Yichen Biopharma. Co. Ltd. BISPECIFIC MOLECULE, ITS MANUFACTURE AND USE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013016220A1 (en) * 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
CN104080808A (zh) * 2011-11-16 2014-10-01 勃林格殷格翰国际有限公司 抗il-36r抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Blockade of IL-36 Receptor Signaling Does Not Prevent from TNF-Induced Arthritis;Anja Derer等;《PLOS ONE》;20141231;第9卷(第8期);e101954 *
The severity of experimental arthritis is independent of IL-36 receptor signaling;Céline Lamacchia等;《Arthritis Research & Therapy》;20131231;第15卷;第1-12页 *

Also Published As

Publication number Publication date
HK1250941A1 (en) 2019-01-18
BR112017022086A2 (pt) 2018-07-03
AU2016248208B2 (en) 2022-03-24
CA2982555A1 (en) 2016-10-20
JP2025163120A (ja) 2025-10-28
DK3283110T3 (da) 2022-05-23
ES2914243T3 (es) 2022-06-08
HK1252009A1 (zh) 2019-05-10
KR102666920B1 (ko) 2024-05-20
RU2017139481A3 (cg-RX-API-DMAC7.html) 2019-09-19
JP7721585B2 (ja) 2025-08-12
JP6913026B2 (ja) 2021-08-04
AU2016248208A1 (en) 2017-11-09
US20200087408A1 (en) 2020-03-19
SG11201708061TA (en) 2017-10-30
RU2017139481A (ru) 2019-05-15
JP7212098B2 (ja) 2023-01-24
PL3283110T3 (pl) 2022-06-27
US12391761B2 (en) 2025-08-19
CN115925932A (zh) 2023-04-07
JP2021118710A (ja) 2021-08-12
JP2018512157A (ja) 2018-05-17
US20180094065A1 (en) 2018-04-05
US11130814B2 (en) 2021-09-28
KR20180002687A (ko) 2018-01-08
US20260022181A1 (en) 2026-01-22
US10526410B2 (en) 2020-01-07
US20210388095A1 (en) 2021-12-16
RU2745898C2 (ru) 2021-04-02
NZ736535A (en) 2024-08-30
CN107847590A (zh) 2018-03-27
MX2017013080A (es) 2018-02-09
EP3283110B1 (en) 2022-04-20
WO2016168542A1 (en) 2016-10-20
EP4176900A1 (en) 2023-05-10
JP2023040236A (ja) 2023-03-22
EP3283110A4 (en) 2019-02-27
EP3283110A1 (en) 2018-02-21
MX2023001791A (es) 2023-03-10

Similar Documents

Publication Publication Date Title
JP7721585B2 (ja) インターロイキン36受容体(il-36r)に対する抗体
US11999783B2 (en) Method of treating autoimmune disease with antibodies against IL-33
HK1252009B (en) Antibodies directed against interleukin 36 receptor (il-36r)
HK40086847A (en) Antibodies directed against interleukin 36 receptor (il-36r)
HK1250941B (en) Antibodies directed against interleukin 36 receptor (il-36r)
BR112017022086B1 (pt) Anticorpo isolado de receptor de interleucina-36 ou fragmento de ligação ao antígeno do mesmo, composição seus usos
HK1231082B (en) Antibodies directed against interleukin-33 (il-33)
HK1231082A1 (en) Antibodies directed against interleukin-33 (il-33)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1252009

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant